|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013072,
umls-concept:C0023981,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0036078,
umls-concept:C0087111,
umls-concept:C0205390,
umls-concept:C0555198,
umls-concept:C1519043,
umls-concept:C2348563,
umls-concept:C2603343
|
|
pubmed:dateCreated |
2006-2-16
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The prognosis of patients suffering from WHO grade 3 and 4 astrocytic glioma remains poor despite surgery, radiation therapy and the use of current chemotherapy regimen. Indeed, the median survival of glioblastoma multiforme (WHO grade 4) patients is at best 14.6 month with only 26.5 percent of the patients still alive after 2 years and the median survival of anaplastic astrocytomas (WHO grade 3) is 19.2 month. Recent evidence suggests that the transcription factor NF-kappaB is constitutively expressed in malignant gliomas and that its inhibition by drugs like Sulfasalazine may block the growth of astrocytic tumors in vitro and in experimental models of malignant gliomas.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-10413158,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-10493363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-10602468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-11007945,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-11054378,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-11302687,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-12520480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-12527911,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-14657528,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-15184909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-15328202,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-15531918,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-15758009,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-15977639,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-2358840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-7588084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16448552-9486988
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
29
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16448552-Administration, Oral,
pubmed-meshheading:16448552-Adult,
pubmed-meshheading:16448552-Aged,
pubmed-meshheading:16448552-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:16448552-Brain Neoplasms,
pubmed-meshheading:16448552-Disease Progression,
pubmed-meshheading:16448552-Double-Blind Method,
pubmed-meshheading:16448552-Female,
pubmed-meshheading:16448552-Glioma,
pubmed-meshheading:16448552-Humans,
pubmed-meshheading:16448552-Male,
pubmed-meshheading:16448552-Middle Aged,
pubmed-meshheading:16448552-Prognosis,
pubmed-meshheading:16448552-Prospective Studies,
pubmed-meshheading:16448552-Sulfasalazine,
pubmed-meshheading:16448552-Survival Analysis,
pubmed-meshheading:16448552-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].
|
|
pubmed:affiliation |
Department of Neurosurgery, University of Liège, Domaine du Sart TIlman, B35, 4000 Liège, Belgium. pierre.robe@ulg.ac.be
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
